A stellar performance from blood products company CSL's core immunoglobulin portfolio has led the healthcare giant to another strong result, with profits jumping 7.5 per cent to $US1.25 billion ($1.86 billion) in the first half.

On a constant currency basis the company's net profit growth climbed into the double digits, hitting 11.3 per cent, while its revenue was also up 11 per cent on a constant currency (9 per cent in a statutory basis), reaching $US4.91 billion for the six months ended December 31 -  slightly ahead of consensus estimates.